Expand all sections

Arachis hypogaea (pinda) allergenen

Palforzia

Extended indication Children of 1 year to less than 4 years of age with peanut allergy.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Arachis hypogaea (pinda) allergenen
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Other chronic immune diseases
Extended indication Children of 1 year to less than 4 years of age with peanut allergy.
Proprietary name Palforzia
Manufacturer Aimmune
Mechanism of action Allergen
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional remarks Ook bekend als AR101

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date September 2023
Expected Registration July 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.